Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

Bibliography

• Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004:80-97
   PubMedGoogle Scholar
• Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog 1993;4:595-613
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring HJ, Marchetto S, Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996;10:238-48
   PubMed Web of Science ®Google Scholar
• McKenna HJ, Stocking KL, Miller RE, Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000;95:3489-97
   PubMed Web of Science ®Google Scholar
• Mackarehtschian K, Hardin JD, Moore KA, Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995;3:147-61
   PubMed Web of Science ®Google Scholar
• Maroc N, Rottapel R, Rosnet O, Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene 1993;8:909-18
   PubMed Web of Science ®Google Scholar
• Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998;91:1101-34
   PubMed Web of Science ®Google Scholar
• Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000;14:1766-76
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring HJ, deLapeyriere O, Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol 1996;95:218-23
   PubMed Web of Science ®Google Scholar
• Zhang S, Fukuda S, Lee Y, Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000;192:719-28
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H, Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the RAS and STAT5 pathways. Blood 2000;96:3907-14
   PubMed Web of Science ®Google Scholar
• Brandts C, Bulent S, Rode M. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005;65:9643-49
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-18
   PubMed Web of Science ®Google Scholar
• Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996;10:588-99
   PubMed Web of Science ®Google Scholar
• Horiike S, Yokota S, Nakao M, Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997;11:1442-6
   PubMed Web of Science ®Google Scholar
• Yokota S, Kiyoi H, Nakao M, Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11:1605-9
   PubMed Web of Science ®Google Scholar
• Breitenbuecher F, Schnittger S, Grundler R, Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009;113:4074-7
   PubMed Web of Science ®Google Scholar
• Griffith J, Black J, Faerman C, The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004;13:169-78
   PubMed Web of Science ®Google Scholar
• Scholl S, Fricke HJ, Sayer HG, Hoffken K. Clinical implications of molecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol 2009;135:491-505
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9
   PubMed Web of Science ®Google Scholar
• Jiang J, Paez JG, Lee JC, Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 2004;104:1855-8
   PubMed Web of Science ®Google Scholar
• Kindler T, Breitenbuecher F, Kasper S, Identification of novel activation mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood 2005;105:335-40
   PubMed Web of Science ®Google Scholar
• Frohling S, Scholl C, Levine RL, Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007;12:501-13
   PubMed Web of Science ®Google Scholar
• Reindl C, Bagrintseva K, Vempati S, Point mutations in the juxtamembrane domain of FLT3 define a new class of activation mutations in AML. Blood 2006;107:3700-7
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance epidemiology and end results stat facts sheets. cancer: acute myeloid leukemia. Available from: http://seer.cancer.gov/statfacts/html/clyl.html. [Accessed 01 September 2010]
   Google Scholar
• Estey E, Dohner H. Acute myeloid leukemia. Lancet 2006;368:1894-907
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrozek K, Dodge RK, Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36
   PubMed Web of Science ®Google Scholar
• Thiede C, Koch S, Creutzig E, Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-20
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J, Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-80
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9
   PubMed Web of Science ®Google Scholar
• Oyarzo MP, Lin P, Glassman A, Acute myeloid leukemia with t(6;9) (p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 2004;122:348-58
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Pizzey AR, Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005;106:3768-76
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66
   PubMed Web of Science ®Google Scholar
• Santos FP, Jones D, Qiao W, Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 2010. [Epub ahead of Print]
   Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59
   PubMed Web of Science ®Google Scholar
• Pautas C, Merabet F, Thomas X, Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808-14
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, Age and acute myeloid leukemia. Blood 2006;107:3481-5
   PubMed Web of Science ®Google Scholar
• Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-15
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-85
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090-8
   PubMed Web of Science ®Google Scholar
• Lang K, Earle C, Foster T, Trends in the treatment of acute myeloid leukemia in the elderly. Drugs Aging 2006;22:943-55
   Web of Science ®Google Scholar
• de Lima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myelogenous leukemia in patients aged 80 years and above. Br J Haematol 1996;93:89-93
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett A, Wheatley K, Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98:1302-11
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24
   PubMed Web of Science ®Google Scholar
• Whitman SP, Maharry K, Radmacher MD, FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010;116:3622-6
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes J, Faderl S, Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010;116:5818-23
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9
   PubMed Web of Science ®Google Scholar
• Abu-Duhier FM, Goodeve AC, Wilson GA, Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001;113:983-8
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W, Prognostic relevance of FLT3-TKD mutations in AML: the combination matters–an analysis of 3082 patients. Blood 2008;111:2527-37
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005;19:1345-9
   PubMed Web of Science ®Google Scholar
• Hawley TS, Fong AZ, Griesser H, Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. Blood 1998;92:2003-11
   PubMed Web of Science ®Google Scholar
• Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996;10:588-99
   PubMed Web of Science ®Google Scholar
• Wiernik PH. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 2010;8:429-36
   PubMedGoogle Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Mori S, Cortes J, Kantarjian H, Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008;49:2246-55
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Ruvolo VR, Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808-18
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Shi YX, Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184-98
   PubMed Web of Science ®Google Scholar
• Crump M, Hedley D, Kamel-Reid S, A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010;51:252-60
   PubMed Web of Science ®Google Scholar
• Pratz KW, Cho E, Levis MJ, A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010;24:1437-44
   PubMed Web of Science ®Google Scholar
• Borthakur G, Kantarjian H, Ravandi F, Phase 1 study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2010;96:62-8
   PubMed Web of Science ®Google Scholar
• Safaian NN, Czibere A, Bruns I, Sorafenib (Nexavar[registered]) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD(+) acute myeloid leukemia. Leuk Res 2009;33:348-50
   PubMed Web of Science ®Google Scholar
• Lee SH, Paietta E, Racevskis J, Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol 2009;84:701-2
   PubMed Web of Science ®Google Scholar
• Metzelder S, Wang Y, Wollmer E, Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567-71
   PubMed Web of Science ®Google Scholar
• Metzelder S, Finck A, Fey M, Sorafenib monotherapy is effective in relapsed and refractoryFlt3-ITD positive acute myeloid leukemia, particularly after allogeneic stem cell transplantation. Blood 2010;116: abstract 3314
   Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-62
   PubMed Web of Science ®Google Scholar
• Serve H, Wagner R, Sauerland C, Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled Phase II trial. Blood 2010;116: abstract 333
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37
   PubMed Web of Science ®Google Scholar
• O'Farrell AM, Foran JM, Fiedler W, An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9:5465-76
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H, A Phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93
   PubMed Web of Science ®Google Scholar
• Yee KW, Schittenhelm M, O'Farrell AM, Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemia cells. Blood 2004;104:4202-9
   PubMed Web of Science ®Google Scholar
• Fiedler W, Krauter J, Gotze K, A Phase I/II study combining sunitinib with standard ara-c/daunorubicin chemotherapy in patients 60 years or older with FLT3 mutated AML. Blood 2010;116: abstract 3285
   PubMed Web of Science ®Google Scholar
• Levis M, Allebach J, Tse KF, A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002;99:3885-91
   PubMed Web of Science ®Google Scholar
• Knapper S, Mills KI, Gilkes AF, The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 2006;108:3494-503
   PubMed Web of Science ®Google Scholar
• Mead AJ, Gale RE, Kottaridis PD, Acute myeloid leukemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with FLT3 internal tandem duplication. Br J Haematol 2008;141:454-60
   PubMed Web of Science ®Google Scholar
• Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004;104:1145-50
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T, A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-70
   PubMed Web of Science ®Google Scholar
• Ravandi F, Kantarjian H, Faderl S, Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 2010;34:752-6
   PubMed Web of Science ®Google Scholar
• Levis M, Smith BD, Beran M, A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. Blood 2005;106: abstract 403
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011. [Epub ahead of print]
   Google Scholar
• Levis M, Brown P, Smith BD, Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006;108:3477-83
   PubMed Web of Science ®Google Scholar
• Propper DJ, McDonald AC, Man A, Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001;19:1485-92
   PubMed Web of Science ®Google Scholar
• Weisberg E, Boulton C, Kelly LM, Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1:433-43
   PubMed Web of Science ®Google Scholar
• Mohi MG, Boulton C, Gu TL, Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004;101:3130-5
   PubMed Web of Science ®Google Scholar
• Bali P, George P, Cohen P, Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 2004;10:4991-7
   PubMed Web of Science ®Google Scholar
• Ahmad R, Liu S, Weisberg E, Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol Cancer Res 2010;8:986-93
   PubMed Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, DeAngelo DJ, Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339-45
   PubMed Web of Science ®Google Scholar
• Stone RM, Fischer T, Paquette R, Phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT 3 mutations is similar to those with wild-type FLT3. Blood 2009;114: abstract 634
   Web of Science ®Google Scholar
• DeAngelo DJ, Stone RM, Heaney ML, Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006;108:3674-81
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stone RM, Heaney ML, Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood 2004;104: abstract 1792
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Amrein PC, Kovacsovics TJ, Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood 2006;108: abstract 158
   Web of Science ®Google Scholar
• Schittenhelm MM, Kampa KM, Yee KW, The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 2009;8:2621-30
   PubMed Web of Science ®Google Scholar
• Zarrinkar PP, Gunawardane RN, Cramer MD, AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-92
   PubMed Web of Science ®Google Scholar
• Levis M, Sato T, Murphy K, FLT3 mutant to wild type allelic ratio and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2009;114: abstract 1716
   PubMed Web of Science ®Google Scholar
• Chao Q, Sprankle KG, Grotzfeld RM, Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem 2009;52:7808-16
   PubMed Web of Science ®Google Scholar
• Cortes J, Foran J, Ghirdaladze D, AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. Blood 2009;114: abstract 636
   Web of Science ®Google Scholar
• James J, Pratz K, Stine A, Clinical pharmacokinetics and FLT3 phosphorylation of AC220, a highly potent and selective inhibitor of FLT3. Blood 2008;112: abstract 2637
   Web of Science ®Google Scholar
• Belli BA, Dao A, Bhagwat S, AC220, a potent and specific FLT3 inhibitor, enhances the cytotoxic effects of chemotherapeutic agents in cell culture and in mouse tumor xenografts. Blood 2009;114: abstract 2052
   PubMed Web of Science ®Google Scholar
• Brigham D, Belli BA, Breider M, AC220, a FLT3 inhibitor, increases survival in two genotypically distinct FLT3-ITD models of acute myeloid leukemia and provides sustained protection following chronic administration. Blood 2009;114: abstract 2053
   PubMed Web of Science ®Google Scholar
• Piloto O, Wright M, Brown P, Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007;109:1643-52
   PubMed Web of Science ®Google Scholar
• Sato T, Yang X, Knapper S, FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011. [Epub ahead of print]
   Google Scholar
• Pratz KW, Sato T, Murphy KM, FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010;115:1425-32
   PubMed Web of Science ®Google Scholar